# Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause

> **NCT05325775** · PHASE1,PHASE2 · COMPLETED · sponsor: **Acer Therapeutics Inc.** · enrollment: 49 (actual)

## Conditions studied

- Post-menopausal Vasomotor Symptoms

## Interventions

- **DRUG:** ACER-801 50 mg BID
- **DRUG:** ACER-801 100 mg BID
- **DRUG:** ACER-801 200 mg BID
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05325775
- **Lead sponsor:** Acer Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-30
- **Primary completion:** 2023-03-04
- **Final completion:** 2023-03-04
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2024-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05325775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05325775, "Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05325775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*